Ascella Biosystems, Inc.
In development — point-of-care molecular diagnostics

Building molecular diagnostics
for use beyond the laboratory.

We are developing AscellaOne, a molecular diagnostic platform that combines isothermal nucleic acid amplification with a handheld reader, a single-use cartridge and a smartphone app. AscellaOne is investigational and is not available for sale.

Development overviewPartner with us
AscellaOne reader AscellaOne app (design mock-up)
Scroll
2020
Founded in San Francisco on technology from a Stanford University laboratory
US·JP
One R&D team across San Francisco, Tokyo and Kashiwa
2fields
Human IVD and veterinary diagnostics in development
RADx
Grant awarded under the US NIH RADx program
Why we do this

Bringing molecular testing closer to where care happens.

Molecular testing is typically performed in central laboratories, which can make it harder to act on results during the same visit. We are developing a compact platform intended to make nucleic acid testing practical closer to the point of care. Its performance will be established through analytical and clinical performance studies.

Development focus

Four technology building blocks.

Isothermal amplification

A single reaction temperature with no thermal cycling, suited to compact instruments.

Freeze-dried reagents

Reagent formulations designed for storage and distribution without a cold chain.

Handheld reader + app

A compact reader operated through a smartphone or tablet app.

Rapid assay design

A proprietary primer design pipeline to add new targets efficiently.

Intended settings

Designed with healthcare settings in mind.

Clinics

Clinics

Primary care and outpatient settings.

Hospital wards

Hospital wards

Wards, ICUs and emergency departments.

Long-term care

Long-term care

Care facilities, with testing performed by healthcare professionals.

Field response

Field response

Disaster and emergency medical response.

Settings shown are development goals. Intended use will be defined through regulatory review in each country.

Milestones

Grant.

NIH RADx grant (2024)

Ascella Biosystems was awarded a grant under the RADx program of the US National Institutes of Health.

Building the next generation of point-of-care testing, together.

We are seeking development, manufacturing and distribution partners for human IVD and veterinary applications.

Get in touch